The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of SARC 022, a phase II multicenter study of linsitinib in pediatric and adult wild-type (WT) gastrointestinal stromal tumors (GIST).
Margaret von Mehren
Consultant or Advisory Role - Novartis; Pfizer
Honoraria - Novartis
Research Funding - NCI
Suzanne George
Consultant or Advisory Role - ARIAD; Bayer; Novartis; Pfizer
Research Funding - ARIAD; Bayer; Novartis; Pfizer
Michael C. Heinrich
Consultant or Advisory Role - ARIAD; MolecularMD; Novartis; Pfizer
Honoraria - Novartis; Onyx
Research Funding - ARIAD; Novartis
Scott Schuetze
No relevant relationships to disclose
Martin G. Belinsky
Research Funding - NCI; Sarcoma Foundation of America
Katherine A. Janeway
Consultant or Advisory Role - Pfizer (U)
Lori Rink
Research Funding - NCI
Kristen N. Ganjoo
No relevant relationships to disclose
Jian Qin Yu
Research Funding - NCI
Jeffrey T. Yap
Research Funding - NCI
John Joseph Wright
No relevant relationships to disclose
Annick D. Van Den Abbeele
Research Funding - NCI